Concourse Financial Group Securities’s AIM ImmunoTech AIM Stock Holding History

Concourse Financial Group Securities’s Portfolio AIM Stock Details AIM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5	Closed	-$308	–	2462
2023 Q2	$335	Hold	5	–	–	﹤0.01%	2256
2023 Q1	$215	Hold	5	–	–	﹤0.01%	2306
2022 Q4	$155	Buy	+5	New	+$232	﹤0.01%	2270
2022 Q3	–	Sell	-5	Closed	-$350	–	2367
2022 Q2	$0	Hold	5	–	–	﹤0.01%	2354
2022 Q1	$1K	Hold	5	–	–	﹤0.01%	2152
2021 Q4	$0	Hold	5	–	–	﹤0.01%	2523
2021 Q3	$1K	Hold	5	–	–	﹤0.01%	2393
2021 Q2	$1K	Buy	+5	New	+$1.07K	﹤0.01%	2352

Other funds holding AIM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Concourse Financial Group Securities's AIM Position: Q3 2023 in Review

Concourse Financial Group Securities sold out of AIM ImmunoTech (AIM) in Q3 2023, closing a stake of 5 shares — an estimated $308 sold.

Concourse Financial Group Securities first reported a position in AIM in Q2 2021 and held it in 8 quarters. The position peaked at $1K in Q1 2022. 34 funds tracked by Wall St. Rank hold AIM as of Q3 2023.

Concourse Financial Group Securities reported no remaining AIM ImmunoTech position as of Q3 2023 after selling out during the quarter.
Concourse Financial Group Securities sold 5 AIM ImmunoTech shares in Q3 2023, an estimated $308.
Concourse Financial Group Securities first reported a position in AIM ImmunoTech in Q2 2021 and held it in 8 quarters.
Concourse Financial Group Securities's AIM ImmunoTech position peaked at $1K in Q1 2022.
34 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q3 2023.

Based on Concourse Financial Group Securities's 13F filing for Q3 2023, filed 25 Oct 2023.